Atea Pharmaceuticals, Inc. (AVIR)
| Market Cap | 348.12M +50.1% |
| Revenue (ttm) | n/a |
| Net Income | -169.52M |
| EPS | -2.12 |
| Shares Out | 80.03M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,849 |
| Open | 4.350 |
| Previous Close | 4.240 |
| Day's Range | 4.350 - 4.350 |
| 52-Week Range | n/a |
| Beta | 0.38 |
| Analysts | Buy |
| Price Target | 8.67 (+99.31%) |
| Earnings Date | May 12, 2026 |
About AVIR
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for AVIR stock is "Buy." The 12-month stock price target is $8.67, which is an increase of 99.31% from the latest price.
News
Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline
BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral a...
Atea Pharmaceuticals Q1 Earnings Call Highlights
Atea Pharmaceuticals NASDAQ: AVIR said it remains on track for two key Phase 3 hepatitis C readouts in 2026 while advancing a newer hepatitis E program aimed at immunocompromised patients with no appr...
Atea Pharmaceuticals Earnings Call Transcript: Q1 2026
Two pivotal phase III HCV trial readouts are expected in 2026, with strong enrollment progress and a robust financial position supporting operations through 2027. The pipeline expanded to include AT-587 for hepatitis E, with first-in-human studies planned mid-year.
Atea Pharmaceuticals Slides: Q1 2026
Atea Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 12, 2026.
Atea Pharmaceuticals Earnings release: Q1 2026
Atea Pharmaceuticals released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Atea Pharmaceuticals Quarterly report: Q1 2026
Atea Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 12, 2026.
Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial Outside North America for Treatment of HC...
Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral a...
Atea Pharmaceuticals Proxy statement: Proxy filing
Atea Pharmaceuticals filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Atea Pharmaceuticals Proxy statement: Proxy filing
Atea Pharmaceuticals filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Atea Pharmaceuticals price target raised to $10 from $6 at Evercore ISI
Evercore ISI raised the firm’s price target on Atea Pharmaceuticals (AVIR) to $10 from $6 and keeps an Outperform rating on the shares.
Atea Pharmaceuticals Earnings Call Transcript: Q4 2025
Phase III HCV program advanced with top-line results expected in 2026, supported by strong cash reserves and a focused commercial strategy. HEV pipeline expanded with AT-587 as lead candidate, targeting a significant unmet need. Cash runway extends through 2027.
Atea Pharmaceuticals Annual report: Q4 2025
Atea Pharmaceuticals has published its Q4 2025 annual report on March 5, 2026.
Atea Pharmaceuticals Earnings release: Q4 2025
Atea Pharmaceuticals released its Q4 2025 earnings on March 5, 2026, summarizing the period's financial results.
Atea Pharmaceuticals Slides: Q4 2025
Atea Pharmaceuticals has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 5, 2026.
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Out...
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026
BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral ...
Atea Pharmaceuticals presents preclinical results of AT-587
Atea Pharmaceuticals (AVIR) announced in vitro results showing that two proprietary oral nucleotide analogs, AT-587 and AT-2490, exhibit promising antiviral profiles as potential first-in-class inhibi...
Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026
Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus Initiation of Phase 1 Clinical Program Anticipated Mid-2026 BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceut...
Atea Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
Phase III trials for a new HCV regimen are on track, with top-line data expected this year and NDA filing in early 2027. The regimen offers high efficacy, short duration, and minimal drug interactions, supporting a test-and-treat model. A new Hepatitis E program is advancing toward proof-of-concept studies.
Atea Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on January 15, 2026.
Atea Pharmaceuticals to highlight strategic priorities for FY26
Atea Pharmaceuticals (AVIR) will present the Company’s strategic priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15 in San Francisco. Atea ended 2025 ...
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026 Topline Results from North American Phase 3 C-BEYOND Trial Expected Mid-2026; Results from C-FORWARD ...
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiv...
Atea Pharmaceuticals completes patient enrollment in C-BEYOND Phase 3 trial
Atea Pharmaceuticals (AVIR) announced completion of enrollment of more than 880 treatment-naive patients in the C-BEYOND Phase 3 trial evaluating the fixed-dose combination, FDC, regimen of bemnifosbu...